OpenURL Connection Search

Select item for more details and to access through your institution.

Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer.
Published in:
2016
By:
- Lapeyre-Prost, Alexandra;
- de Larauze, Marine Hug;
- Chibaude, Benoist;
- Garcia, Marie Line;
- Guering-Meyer, Veronique;
- Bouché, Olivier;
- Boucher, Eveline;
- Ychou, Marc;
- Dauba, Jérôme;
- Obled, Stéphane;
- Lièvre, Astrid;
- Malka, David;
- Faroux, Roger;
- Bonnet, Isabelle;
- Taieb, Julien;
- André, Thierry;
- Hug de Larauze, Marine;
- Chibaudel, Benoist;
- Groupe Coopérateur Multidisciplinaire en Oncologie, the Fédération Francophone de la Cancérologie Digestive, and the UNICANCER Investigators of the PRODIGE Intergroup
Publication type:
journal article
Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial.
Published in:
PLoS ONE, 2016, v. 11, n. 6, p. 1, doi. 10.1371/journal.pone.0157067
By:
- Hamidou, Zeinab;
- Chibaudel, Benoist;
- Hebbar, Mohamed;
- Hug de Larauze, Marine;
- André, Thierry;
- Louvet, Christophe;
- Brusquant, David;
- Garcia-Larnicol, Marie-Line;
- de Gramont, Aimery;
- Bonnetain, Franck
Publication type:
Article
Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer: The results of the GERCOR OPTIMOX 1 study.
Published in:
Health & Quality of Life Outcomes, 2014, v. 12, n. 1, p. 1, doi. 10.1186/1477-7525-12-69
By:
- Diouf, Momar;
- Chibaudel, Benoist;
- Filleron, Thomas;
- Tournigand, Christophe;
- de Larauze, Marine Hug;
- Garcia-Larnical, Marie-Line;
- Dumont, Sarah;
- Louvet, Christophe;
- Perez-Staub, Nathalie;
- Hadengue, Alexandra;
- de Gramont, Aimery;
- Bonnetain, Franck
Publication type:
Article
Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study.
Published in:
2014
By:
- Diouf, Momar;
- Chibaudel, Benoist;
- Filleron, Thomas;
- Tournigand, Christophe;
- Hug de Larauze, Marine;
- Garcia-Larnicol, Marie-Line;
- Dumont, Sarah;
- Louvet, Christophe;
- Perez-Staub, Nathalie;
- Hadengue, Alexandra;
- de Gramont, Aimery;
- Bonnetain, Franck
Publication type:
journal article
STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.
Published in:
BMC Cancer, 2015, v. 15, n. 1, p. 1, doi. 10.1186/s12885-015-1503-7
By:
- Chibaudel, Benoist;
- Bonnetain, Franck;
- Tournigand, Christophe;
- de Larauze, Marine Hug;
- de Gramont, Armand;
- Laurent-Puig, Pierre;
- Paget, Jérôme;
- Hadengue, Alexandra;
- Notelet, Dominique;
- Benetkiewicz, Magdalena;
- André, Thierry;
- de Gramont, Aimery
Publication type:
Article
STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer
Published in:
BMC Cancer, 2015, v. 15, n. 1, p. 496, doi. 10.1186/s12885-015-1503-7
By:
- Chibaudel, Benoist;
- Bonnetain, Franck;
- Tournigand, Christophe;
- de Larauze, Marine Hug;
- de Gramont, Armand;
- Laurent-Puig, Pierre;
- Paget, Jérôme;
- Hadengue, Alexandra;
- Notelet, Dominique;
- Benetkiewicz, Magdalena;
- André, Thierry;
- de Gramont, Aimery
Publication type:
Article
STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.
Published in:
2015
By:
- Chibaudel, Benoist;
- Bonnetain, Franck;
- Tournigand, Christophe;
- de Larauze, Marine Hug;
- de Gramont, Armand;
- Laurent-Puig, Pierre;
- Paget, Jérôme;
- Hadengue, Alexandra;
- Notelet, Dominique;
- Benetkiewicz, Magdalena;
- André, Thierry;
- de Gramont, Aimery
Publication type:
journal article

Found: 7

Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer.

Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial.

Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer: The results of the GERCOR OPTIMOX 1 study.

Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study.

STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.

STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer

STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.